Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering DrugsHye Won Lee, Su‐Yen Goh, Marcus Thuresson et al.|Journal of the American College of Cardiology|2018Cited by 465
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Matthias Saathoff, Dianna J. Magliano et al.|The Lancet Diabetes & Endocrinology|2020Cited by 93
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based studyDunya Tomic, Dianna J. Magliano, Jedidiah I Morton et al.|The Lancet Diabetes & Endocrinology|2022Cited by 72